2. subjects have no cardiovascular disease, with sitting blood pressure: 90mmHg ≤SBP\<140mmHg and 60mmHg ≤DBP\<90mmHg;
3. body mass index (BMI) between 19 to 26, and a total body weight: male ≥50.0 kg and \<90.0 kg; female ≥45.0 kg and \<90.0 kg
4. Participant in general good health. No clinically significant findings in laboratory parameters or clinically significant abnormality on electrocardiogram, X-ray, Echocardiograph and B-type ultrasonic
You may not be if
1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin \> 1.5 x ULN during screening/baseline;
3. Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination, hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) test positive;
4. Known postural hypotension; the numeric difference of systolic blood pressure between both upper limbs \>20mmHg；
5. A clinical history of arrhythmia；subjects with Electrocardiogram QTc prolongation（male\>450ms；female\>460ms）during screening；
6. A clinical history of hyperuricemia；serum uric acid \> the upper limit of normal value (ULN) during screening;
7. A clinical history of diabetes；fasting plasma glucose or hemoglobin A1c exceeded the upper limit of normal value (ULN) during screening;
8. Subjects with previous GI discomfort -abdominal pain, diarrhea, and nausea 3 months prior to screening；
9. A clinical history of acute or chronic kidney disease;
10. Subjects with severe trauma or surgery within 3 months prior to the screening； 11.3 months prior to screening involved in any drug or medical device clinical subjects, or within 5 half-life of drugs (test drug half-life more than 3 months) before screening;
12.Pregnant or Serum β-hCG \> 5mIU/mL at baseline or women who are breastfeeding; etc.
Clareo Health | The PK/PD Study of SHR0532 Tablets in Healthy Subjects
